109 related articles for article (PubMed ID: 8054279)
41. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
Han YC; Zeng XX; Wang R; Zhao Y; Li BL; Song M
Ai Zheng; 2007 Jan; 26(1):48-53. PubMed ID: 17222367
[TBL] [Abstract][Full Text] [Related]
42. [Expression and significance of urokinase-type plasminogen activator in breast cancer].
Xiao J; Zhang G; Xia W
Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):196-8. PubMed ID: 11776834
[TBL] [Abstract][Full Text] [Related]
43. [Prognostic significance of plasminogen activator inhibitor-1 (PAI-1) in primary breast carcinoma].
Fersis N; Kaufmann M; Kramer MD; Wittmann G; Wallwiener D; Bastert G
Geburtshilfe Frauenheilkd; 1996 Jan; 56(1):28-34. PubMed ID: 8852783
[TBL] [Abstract][Full Text] [Related]
44. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
Foekens JA; Look MP; Bolt-de Vries J; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Jan; 79(2):300-7. PubMed ID: 9888472
[TBL] [Abstract][Full Text] [Related]
45. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
[TBL] [Abstract][Full Text] [Related]
46. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.
Malmström P; Bendahl PO; Boiesen P; Brünner N; Idvall I; Fernö M;
J Clin Oncol; 2001 Apr; 19(7):2010-9. PubMed ID: 11283134
[TBL] [Abstract][Full Text] [Related]
47. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
48. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer.
Nooter K; Brutel de la Riviere G; Look MP; van Wingerden KE; Henzen-Logmans SC; Scheper RJ; Flens MJ; Klijn JG; Stoter G; Foekens JA
Br J Cancer; 1997; 76(4):486-93. PubMed ID: 9275026
[TBL] [Abstract][Full Text] [Related]
49. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M
Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085
[TBL] [Abstract][Full Text] [Related]
50. Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue.
Hennipman A; van Oirschot BA; Smits J; Rijksen G; Staal GE
Cancer Res; 1989 Feb; 49(3):516-21. PubMed ID: 2910471
[TBL] [Abstract][Full Text] [Related]
51. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
52. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.
Scorilas A; Diamandis EP; Levesque MA; Papanastasiou-Diamandi A; Khosravi MJ; Giai M; Ponzone R; Roagna R; Sismondi P; López-Otin C
Clin Cancer Res; 1999 Jul; 5(7):1778-85. PubMed ID: 10430082
[TBL] [Abstract][Full Text] [Related]
53. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
54. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Horch HH
Mund Kiefer Gesichtschir; 2004 May; 8(3):180-90. PubMed ID: 15138856
[TBL] [Abstract][Full Text] [Related]
55. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
56. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Harbeck N; Kates RE; Schmitt M
J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
[TBL] [Abstract][Full Text] [Related]
57. Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis.
Shao GL; Wang MC; Fan XL; Zhong L; Ji SF; Sang G; Wang S
Technol Cancer Res Treat; 2018 Jan; 17():1533034617754024. PubMed ID: 29529946
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.
Bouchet C; Spyratos F; Hacène K; Durcos L; Bécette V; Oglobine J
Br J Cancer; 1998 May; 77(9):1495-501. PubMed ID: 9652768
[TBL] [Abstract][Full Text] [Related]
59. Effect of quercetin on activities of protein kinase C and tyrosine protein kinase from HL-60 cells.
Kang TB; Liang NC
Zhongguo Yao Li Xue Bao; 1997 Jul; 18(4):374-6. PubMed ID: 10072927
[TBL] [Abstract][Full Text] [Related]
60. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
